NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
2 Months : From Oct 2019 to Dec 2019
Prescription-strength CelleRx to gently clean skin and ease post-procedure discomfort is now available without a prescription at www.CelleRx.com
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces the availability of full-strength CelleRx for consumer purchase without a prescription in the U.S. at CelleRx.com. CelleRx is a skin and wound cleanser based on NovaBay’s proprietary pure hypochlorous formulation, and is proven to gently clean and ease discomfort following aesthetic dermatology and cosmetic surgery procedures.
“We are delighted to make prescription-strength CelleRx available without a prescription directly to customers through our new website,” said Justin Hall, NovaBay CEO. “We are entering the market with a soft launch to test the brand and create awareness, with more extensive marketing to begin in early 2020.
“CelleRx has all the characteristics of a successful skin and wound cleanser: it is known to quickly kill bacteria in vitro, it prevents the build-up of biofilm that can delay wound healing and it is safe for underlying tissue. We view this as a significant advantage given that of the 20 wound cleansers we tested, most lacked two or even all three of these characteristics,” he added. “Because of its amazing safety profile, CelleRx has applicability to almost all dermatological treatments, including cosmetic laser surgeries, laser resurfacing, chemical peels, liposuction, tattoo removal, laser hair removal and microdermabrasion.”
CelleRx is based on Neutrox®, the same pure hypochlorous acid formulation as NovaBay’s flagship product Avenova®, which is proven to treat the underlying cause of blepharitis and bacterial dry eye. CelleRx has been cleared as a medical device by the U.S. FDA and has CE Marking in the EU. Hypochlorous acid is a natural agent produced by white blood cells as a function of the innate immune system. In solution, hypochlorous acid kills both gram-negative and gram-positive bacteria, as well as fungi and biofilms within seconds. CelleRx is well tolerated and in vitro studies show it quickly neutralizes super antigens (toxins) and pro-inflammatory cytokines without interfering with the growth of underlying new tissue. Safe and effective, CelleRx is non-irritating, reduces redness and swelling, doesn’t dry or stain skin when applied and does not generate antibiotic resistance.
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company focusing on commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global, topical anti-infective market with its two distinct product categories: the NEUTROX® family of products and the AGANOCIDE® compounds. The Neutrox family of products includes AVENOVA® for the eye care market, NEUTROPHASE® for wound care market, and CELLERX® for the aesthetic dermatology market. The Aganocide compounds, still under development, have target applications in the dermatology and urology markets.
This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies and future focus, the launch of a new product and the impact it may have on our future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, potential uses of our product, market acceptance, and any potential regulatory problems. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay informed on NovaBay’s progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
View source version on businesswire.com: https://www.businesswire.com/news/home/20191104005160/en/
President and Chief Executive Officer
LHA Investor Relations